AYA.AX Artrya Limited (ASX) pre-market 14 Feb 2026: A$3.10 after drop, earnings key

AYA.AX stock opens pre-market at A$3.10, down 10.92% after a recent pullback. We note Artrya Limited (AYA.AX) trades on the ASX with market cap A$386.42m and upcoming earnings due 24 Feb 2026. The company sells Salix, an AI imaging product for coronary disease detection, which keeps it in our AI stocks watchlist. Using Meyka AI-powered market analysis platform, we examine valuation, technical signals, and model forecasts ahead of the report.

Market snapshot and price action for AYA.AX stock

AYA.AX stock is trading A$3.10 pre-market after a A$0.38 decline from yesterday. Volume is 518,040 shares versus a 90-day average of 712,393, and intraday range sits between A$3.09 and A$3.33.

Year range runs from A$0.56 to A$5.24, the 50-day average is A$4.06, and the 200-day average is A$2.39. These short- and long-term levels frame support near A$3.00 and resistance near A$4.20.

AYA.AX analysis: financials and valuation

Artrya reports negative earnings with EPS -A$0.18 and a trailing PE of -18.94. The balance sheet shows cash per share A$0.11 and a very high price-to-book of 16.50, underlining expensive headline valuations relative to book value.

Other ratios flag risk: price-to-sales is 13,800.76, current ratio 8.27, and R&D spend equals 197.50% of revenue TTM. Revenue per share is tiny at A$0.00, which magnifies valuation sensitivity to small revenue moves.

Technical outlook and trading signals for AYA.AX

Momentum indicators show short-term strength and overbought conditions: RSI 70.89 and MFI 82.92. ADX at 40.86 indicates a strong trend, while MACD histogram is positive at 0.09, suggesting bullish momentum near resistance.

Short-term traders should watch support A$3.09 and resistance A$3.33, with a wider resistance zone near the 50-day band at A$4.06. Low relative volume versus average suggests the move lacks broad participation.

Meyka AI grade, forecasts and AYA.AX forecast comparison

Meyka AI rates AYA.AX with a score out of 100: 63.30 | Grade B | Suggestion: HOLD. This grade factors S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects monthly A$3.56, quarterly A$5.83, and 12-month A$7.90. Versus the current A$3.10, that implies model upside of 14.84% (monthly), 87.74% (quarterly), and 154.78% (12-month). Forecasts are model-based projections and not guarantees.

AYA.AX risks and catalysts for AI investors

Key catalysts include the 24 Feb 2026 earnings announcement and adoption of Salix in clinics. Positive trial results or new contracts could swing sentiment and justify higher multiples.

Principal risks are continuing negative earnings, thin revenue base, and high valuation ratios. A small revenue shortfall could trigger steep downside given the elevated price-to-book and price-to-sales metrics.

Trading strategy for AI stocks and AYA.AX investment approach

For AI-focused investors, treat AYA.AX as a high-volatility, high-upside play tied to product adoption. Consider staged exposure and set stops below A$2.80 to limit downside. Use earnings on 24 Feb 2026 as a re-evaluation point.

We link competitor data for context: see investing comparisons source and source. Also view the Meyka stock page for AYA.AX for live updates Meyka stock page.

Final Thoughts

Key takeaways: AYA.AX stock trades pre-market at A$3.10, reflecting a near-term pullback ahead of earnings on 24 Feb 2026. Fundamentals show negative EPS (-A$0.18) and stretched valuation metrics like PB 16.50 and extreme price-to-sales. Technicals display short-term strength with RSI 70.89 and ADX 40.86, but volume lags average. Meyka AI’s forecast model projects A$7.90 in 12 months, implying ~154.78% upside from today. That projection supports a constructive medium-term view if Artrya converts pilot deals to recurring revenue. However, high valuation and operating losses increase execution risk. We rate this a speculative, AI-sector exposure suitable for investors who accept high volatility and event-driven risk. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.